Mestag and Janssen to identify novel therapeutic targets
Mestag Therapeutics, a breakthrough inflammatory disease and immuno-oncology company based in Cambridge, has agreed a target discovery, option and licence agreement with Janssen Biotech, Inc. – one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The deal, facilitated by Johnson & Johnson Innovation, will leverage Mestag’s specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets.
Mestag will interrogate fibroblast subpopulations across diseases and their interactions with key aspects of the immune system. The company grants to Janssen an option to an exclusive license to develop and commercialise therapeutics directed against up to two targets that may arise from the collaboration, in exchange for option fees, milestones, and royalties. Financial terms were not disclosed.
As part of the collaboration, David Lee, Global Immunology Therapeutic Area Head, Janssen Research & Development, LLC, will join Mestag’s Scientific Advisory Committee. Alongside the collaboration, Mestag will continue to develop the company’s own inflammatory disease and cancer programs as it progresses its pipeline of first-in-class therapeutics towards the clinic.
“Mestag’s vision is to leverage our unique fibroblast biology platform and state-of-the-art data analytics to enable precision medicine breakthroughs in disease areas with high unmet medical need,” said Susan Hill, CEO of Mestag.
Mestag was founded in 2020 to develop new medicines for people affected by inflammatory disease and cancer.